ORIC Pharmaceuticals Inc [ORIC] stock prices are up 15.26% to $12.39 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ORIC shares have gain 11.12% over the last week, with a monthly amount glided 44.91%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ORIC Pharmaceuticals Inc [NASDAQ: ORIC] stock has seen the most recent analyst activity on October 31, 2024, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $20. Previously, Stifel started tracking the stock with Buy rating on September 06, 2024, and set its price target to $20. On February 23, 2024, Cantor Fitzgerald initiated with a Overweight rating. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $8 on September 22, 2023. H.C. Wainwright upgraded its rating to a Buy but $16 remained the price target by the analyst firm on March 23, 2023. Guggenheim upgraded its rating to Buy for this stock on March 21, 2023, but kept the price target unchanged to $15. In a note dated March 16, 2023, Oppenheimer upgraded an Outperform rating on this stock but restated the target price of $14.
The stock price of ORIC Pharmaceuticals Inc [ORIC] has been fluctuating between $6.33 and $16.65 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. ORIC Pharmaceuticals Inc [NASDAQ: ORIC] shares were valued at $12.39 at the most recent close of the market. An investor can expect a potential return of 61.42% based on the average ORIC price forecast.
Analyzing the ORIC fundamentals
Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -87.62%, Pretax Profit Margin comes in at -77.94%, and Net Profit Margin reading is -77.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.42 and Total Capital is -0.48. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.21 points at the first support level, and at 10.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.09, and for the 2nd resistance point, it is at 13.80.
Ratios To Look Out For
It’s worth pointing out that ORIC Pharmaceuticals Inc [NASDAQ:ORIC]’s Current Ratio is 13.15. In addition, the Quick Ratio stands at 13.15 and the Cash Ratio stands at 2.08.
Transactions by insiders
Recent insider trading involved Piscitelli Dominic, Chief Financial Officer, that happened on Dec 16 ’24 when 8851.0 shares were sold. Chief Medical Officer, Multani Pratik S completed a deal on Dec 16 ’24 to sell 8850.0 shares. Meanwhile, PRESIDENT AND CEO Chacko Jacob sold 24660.0 shares on Dec 16 ’24.
